Evidence record 9525 · automatically gathered

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models

Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease with a high mortality rate. Putative drug targets in IPF have failed to translate into effective therapies at the clinical level. We identify TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic target using a predictive artificial intelligence (AI) approach. Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic ac

Record details

Published: 8 March 2024
Source: OpenAlex
Category: Research
Topics: Healthcare
Retrieved: 14 July 2026

source-onlyevidence status

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (8 March 2024), “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models,” evidence record 9525, https://ethics.ai/record/9525 (originally published by OpenAlex).

JSON

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.